Role of regulatory agencies in translating pharmacogenetics to the clinics

Clinical Cases in Mineral and Bone Metabolism

Volumn 6, Issue 1, 2009, Pages 29-34

  Prasad, Krishna ^a,b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b EMEA ^*  (United Kingdom)

Author keywords

Clinical practise; Drug regulation; Pharmacogenetic testing; Pharmacogenomics; Regulatory guidance

Indexed keywords

CLINICAL PRACTICE; DNA POLYMORPHISM; DRUG INDUSTRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH CARE PERSONNEL; IMMUNOHISTOCHEMISTRY; MEDICAL EDUCATION; MEDICAL SOCIETY; NURSING EDUCATION; PHARMACOGENETICS; PHARMACOGENOMICS; PRACTICE GUIDELINE; REGULATORY MECHANISM; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 76549090371     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (19)

1. Meletis J, Konstantopoulos K. Favism - from the 'avoid fava beans' of Pythagoras to the present . Haema. 2004;7(1):17-21 ICID:7603.
2. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurinemethyltransferase activity. Am J Hum Genet. 1980;32:651-662.
3. Woelderink A, Ibarreta D, Hopkins MM, Rodriguez-Cerezo E. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J. 2006;6:3-7.
4. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008 mar 6; 358(10):999-1008.
5. Caldwell M, Award T, Johnson JA et al. CYP4F2 genetic variant alters required warfarin dose. Blood. Apr 15;111(8):4106-12. Epub 2008 Feb 4.
6. O'Kane DJ, Weinshilboum RM, Moyer TP. Pharmacogenomics and reducing the frequency of adverse events. Pharmacogenomics. 2003;4(1):1-4.
7. http://www.emea.europa.eu/humandocs/Humans/EPAR/herceptin/herceptin.htm
8. Payne K, Newman W, Fargher E et al. TPMT testing in rheumatology; any better than routine monitoring. Rheumatology. 2007 May;46(5):727-9. Epub 2007 Jan 25.
9. ftp://ftp.jrc.es/pub/EURdoc/eur22214en.pdf; IPTS report for European commission on HER-2 and TPMT testing in EU.
10. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppresion during azathioprine therapy. Gastroenterology. 2000;118:1025-30.
11. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Ziagen/101999en8b.pdf
12. http://en.wikipedia.org/wiki/The-Canon-of-Medicine
13. Craig Brater D, Walter JD. Clinical pharmacology in the Middle Ages: Principles that presage the 21st century. Clinical Pharmacology & Therapeutics. 2000;67(5):447-450 [448].
14. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200-5.
15. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004 Jul 3;329(7456):15-9.
16. http://www.emea.europa.eu/pdfs/human/ich/43798606en.pdf, ICH, E-15, Nov 2007.
17. http://www.emea.europa.eu/htms/human/humanguidelines/multidiscipline.htm, Pharmacogenomics.
18. http://www4.od.nih.gov/oba/SACGHS/reports/SACGHS-PGx-Report.pdf. The report for the Secretary of State, DHSS, USA.
19. Ralston RH, Uitterlinden AG, Brandi ML et al. Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study. PLoS Med. 2006 Apr;3(4):e90. Epub 2006 Feb 21. Erratum in: PLoS Med. 2006 May;3(5):e90.